Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42319   clinical trials with a EudraCT protocol, of which   6970   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001897-13
    Sponsor's Protocol Code Number:ITM-LET-01
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:GB - no longer in EU/EEA
    Date on which this record was first entered in the EudraCT database:2017-06-20
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2016-001897-13
    A.3Full title of the trial
    A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium 177-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
    A.3.2Name or abbreviated title of the trial where available
    COMPETE
    A.4.1Sponsor's protocol code numberITM-LET-01
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT03049189
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorITM Solucin GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportITM Solucin GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPSI Pharma Support Poland Sp. z o.o.,
    B.5.2Functional name of contact pointProject Manager
    B.5.3 Address:
    B.5.3.1Street AddressWisniowy Business Park C, ul. 1-go Sierpnia 6A
    B.5.3.2Town/ cityWarsaw
    B.5.3.3Post code02-134
    B.5.3.4CountryPoland
    B.5.4Telephone number+4822210 02004836
    B.5.5Fax number+4822210 0200
    B.5.6E-mailmaciej.wos@psi-cro.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Afinitor
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAfinitor
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEverolimus
    D.3.9.1CAS number 159351-69-6
    D.3.9.3Other descriptive nameEVEROLIMUS
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/14/1269
    D.3 Description of the IMP
    D.3.1Product name177Lu-Edotreotide
    D.3.2Product code 177Lu-DOTATOC
    D.3.4Pharmaceutical form Solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INN177Lu-Edotreotide
    D.3.9.3Other descriptive name177LU-DOTA-TYR3-OCTREOTIDE
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit GBq gigabecquerel(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number7.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product Yes
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Afinitor
    D.2.1.1.2Name of the Marketing Authorisation holderNovartis Europharm Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAfinitor
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEverolimus
    D.3.9.1CAS number 159351-69-6
    D.3.9.3Other descriptive nameEVEROLIMUS
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)
    E.1.1.1Medical condition in easily understood language
    This trial aims to investigate metastasised and / or locally advanced neuroendocrine tumours (NET) in patients with pancreatic NET or non-functional gastroenteric NET.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10077559
    E.1.2Term Gastroenteropancreatic neuroendocrine tumour disease
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the efficacy of PRRT with 177Lu-edotreotide to prolong progression-free survival (mPFS) in patients with inoperable, progressive, SSTR+ GEP-NET, compared to everolimus
    E.2.2Secondary objectives of the trial
    Key secondary objectives
    1.To assess objective response rates (ORR), defined as the proportion of patients achieving partial response (PR) or complete response (CR) as best outcome after treatment with 177Lu-edotreotide vs. everolimus
    2. To assess overall survival (OS), defined as the time from date of randomisation until death

    Exploratory secondary objectives
    3. To assess the duration of disease control (DDC) defined as the time of initial diagnosis of response (SD, PR or CR) until diagnosis of progression, after treatment with 177Lu-edotreotide vs. everolimus
    4. To determine disease control rates (DCR)
    5. To determine functional response rates (FRR)
    6. To assess the safety and tolerability of 177Lu-edotreotide in GEP-NET patients
    7. To determine the health-related quality of life (HRQL) in GEP-NET patients during and after therapy
    8. To evaluate symptomatic tumour response
    9. To evaluate the impact of patient characteristics
    10. To evaluate the impact of tumour histology
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Title: Sub-study A: Repetitive Full Dosimetry Imaging
    Objective: The total absorbed doses (AD) to kidneys and tumour from four cycles of 177Lu-edotreotide (D1 – D4) will be estimated, by linear extrapolation of the AD measured during D1 with 7.5 GBq ± 0.7 GBq to the full dose of 30 GBq. Dosimetry will be measured, using serial planar and single time point SPECT imaging. To verify the accuracy of total AD estimations, based on a linear extrapolation of AD measured during D1, full dosimetric imaging will be repeated during subsequent cycles (D2 – D4) in a subgroup of approximately 20 patients, ready and able to undergo repetitive dosimetric imaging. At selected sites only.

    Title: Sub-study B: 3D Dosimetry SPECT/CT Imaging
    Objective: Abdominal SPECT images (1-2 bed positions, covering liver, kidneys, tumour, as appropriate) will be acquired in a subgroup of approximately 20 patient of 177Lu-edotreotide group in addition to the compulsatory planar images at the following time points of 0.5, 6, 24 and 72 – 96 h after injection of 177Lu-edotreotide. SPECT imaging will be performed after planar imaging. The absorbed doses determined by 3D dosimetry, will be analysed in comparison to absorbed doses values obtained by planar (2D) and hybrid (2D/3D) dosimetry. At selected sites only.

    Sub-study C:
    Objective: This sub-study C will be conducted to assess the in vivo (in a living organism) stability of 177Lu-edotreotide and its radioacitivity in bone marrow. The additional examinations for this sub-study will be only performed during the first treatment cycle of 177Lu-Edotreotide in a subgroup of 20 patients in total at selected sites only.
    E.3Principal inclusion criteria
    1. Written informed consent
    2. Male or female ≥18 years of age
    3. Histologically confirmed diagnosis of well-differentiated neuroendocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET), grade G1 or G2 (Ki-67 < 20%), unresectable or metastatic
    4. Availability of existing biopsy specimen from primary tumour or metastasis or, if unavailable, willingness to undergo current biopsy for secondary central analysis
    5. Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with ≥1 cm in longest diameter, and ≥ 2 radiological tumour lesions in total. A maximum of 5 target lesions visible on CT/MRI will be defined, thereof not more than 2 lesions per organ
    6. Somatostatin receptor positive (SSTR+) disease, as evidenced by SSTR imaging (SRI) within 4 months prior to randomisation, as locally authorised, by:
    • 68Ga-based SSTR PET imaging (68Ga-edotreotide or 68GaDOTATATE), or
    • 111In-pentetreotide SSTR SPECT/planar imaging, or
    • 99mTc-octreotide SSTR SPECT/planar imaging
    All target lesions and ≥ 90% of non-target lesions need to be positive for SSTR; this relates to lesions of at least 15 mm in diameter acquired on SRI images with SPECT, and of at least 10 mm in diameter acquired on SRI images with PET systems.
    7. The patient must have progressive disease based on RECIST 1.1 Criteria as evidenced by two morphological imaging examinations made with the same imaging method (either CT or MRI), within a maximum of 36 months prior to randomisation. The most recent scan must not be older than 90 days prior to randomisation date. The minimum interval between the two scans must be ≥ 90 days.
    8. Karnofsky performance status (KPS) scale ≥ 70
    9. Life expectancy of at least 6 months
    10. Glomerular filtration rate (GFR, CKD-EPI) ≥ 60 mL/min/1.73 m^2
    11. For patients included in France only, verification and confirmation of their affiliation with a social security
    12. Patients with functional P-NETs who require SSA for symptom control may continue SSA treatment throughout the study, on condition that:
    a) they have been on a stable dose for at least three months prior to study enrolment
    b) that progressive disease has been diagnosed while under such stable dose
    E.4Principal exclusion criteria
    A patient will be excluded from participation in the trial if one or more of the following criteria are met:
    1. Known hypersensitivity to edotreotide or everolimus
    2. Known hypersensitivity to DOTA, lutetium-177, or any excipient of edotreotide or everolimus or any other Rapamycin derivative
    3. Known hypersensitivity to lysine, arginine, or any excipient of the nephroprotective amino acid solution
    4. Prior exposure to any peptide receptor radionuclide therapy (PRRT), including 177Lu-edotreotide, 90Y-edotreotide or other SSTR-targeting agents (e.g. 177Lu-octreotate or high-dose 111In-pentetreotide)
    5. Prior therapy with mTor inhibitors
    6. Prior EFR (external field radiation) to GEP-NET lesions or radioembolisation therapy (e.g. 90Y microspheres,
    131I-lipiodol) with administration to the liver
    7. Prior therapy with chemotherapy, immunotherapy, interferon, chemo-embolisation, bland embolisation, cyclosporine-A within 4 weeks before randomisation; any new cancer treatment between screening and randomisation
    8. Therapy with an investigational compound and/or medical device within 30 days or 5 half-life periods (whichever is longer) prior to randomisation
    9. Subjects who have received a live vaccine up to 4 weeks prior to first dose
    10. Current therapy with any prohibited medication (see 6.1.1)
    11. Ongoing toxicity grade 2 according to CTCAE version 4.03 from previous standard or investigational therapies
    12. Indication for surgical lesion removal with curative potential
    13. Planned (for the period of study participation): chemotherapy, immunotherapy, interferon, radiation therapy, chemo-embolisation, bland embolisation, radio-embolisation, treatment with cyclosporine-A
    14. Neuroendocrine tumours, not meeting the inclusion criteria:
    • With known non-GEP-NET origin (e.g. pulmonary or gonadal primaries)
    • Functional GE-NET
    • Explicit diagnosis of unknown primary (CUP)
    • Poorly differentiated neuroendocrine carcinomas(G3)
    • NET for which no histological specimen for secondary histological analysis can be obtained
    15. Total hepatic tumour burden > 70%
    16. Brain metastases
    17. Other malignancy within previous 5 years (except basalioma)
    18. Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator
    19. Renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments, as follows:
    • Renal
    o Serum potassium > 5.0 mmol/L
    o Renal obstruction
    o Known nephropathy from any cause
    • Hepatic
    o Total bilirubin >1.5 x ULN
    o AST or ALT > 2.5 x ULN
    o Alkaline phosphatase > 5 x ULN
    o Albumin < 3 g/dL, unless prothrombin time is within normal range
    o Known cirrhosis or other distinctly restricted liver function
    • Cardiovascular
    o New York Heart Association classification III & IV
    o Uncontrolled hypertension
    • Haematopoietic
    o Platelets ≤ 80 * 10^9/L
    o Absolute neutrophil count (ANC) < 1 x 10^9 cells/L
    20. Pregnant or breast-feeding women. Female patients of childbearing potential or male patients with female partners of childbearing potential, unless willing to practice full and true sexual abstinence or being surgically/permanently sterile or with a history of hysterectomy for women, not willing to practice effective contraception by using: a non-oral, injected or implanted non-oestrogen progesterone based hormonal method, male condom, vaginal diaphragm, cervical cap, intrauterine device, during the study period and for 56 days after treatment in the everolimus group and 66 days in the PRRT group (10 half-lives of 177Lu) after the last treatment cycle.
    21. Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) or any other vulnerable population to that sense (e.g. persons institutionalised, incarcerated etc.).
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is progression-free survival (PFS). Diagnosis of progression and liver tumour burden will be established based on radiological information from morphological imaging (MRI and/or CT) according to RECIST 1.1. Stratification will be made for primary tumour origin (GE-NET vs. P-NET) and prior medical therapy (1st line vs. 2nd line). Tumour grade (G1, G2), and baseline Karnofsky score will be used for further statistical subgroup analyses.


    E.5.1.1Timepoint(s) of evaluation of this end point
    The primary endpoint is progression-free survival (PFS), determined as time elapsed between randomisation and the date of first objective report of tumour progression (evaluated by RECIST criteria, 1.1), or death. Diagnosis of progression will be established based on radiological information from morphological imaging (MRI / CT) using RECIST 1.1. Status of disease will be defined as one of the following options: Complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).
    E.5.2Secondary end point(s)
    Secondary endpoints include parameters of morphological and functional tumour response such as objective response rate (ORR), overall survival (OS), disease control rates (DCR), as well as duration of disease control (DDC), safety, health-related quality of life (HRQL). Furthermore, exploratory analyses will be performed on patient and tumour characteristics, as well as the degree of 177Lu-edotreotide uptake for traits predicting PRRT efficacy.
    E.5.2.1Timepoint(s) of evaluation of this end point
    At the end of study
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Dosimetry: To assess differences in tumour and kidney radiation dose estimates, obtained with 2D compared to hybrid (2D/3D) and 3D (SPECT) imaging
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA38
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    France
    Germany
    Italy
    Netherlands
    Poland
    South Africa
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is defined as the last visit of the last patient or the last date of follow-up of toxicities, if required (whichever is the later)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 200
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Study patients experiencing disease progression under everolimus will perform EOS visit and terminate study participation. Subsequently, they may be offered 177Lu-edotreotide therapy based on the personal judgement of the Investigator/treating physician if he/she considers it to be appropriate and beneficial for the individual patient. The investigator can request from the sponsor the provision of study drug to individual patients on a "named" patient basis as a bona fide unsolicited order.

    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-08-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-04-20
    P. End of Trial
    P.End of Trial StatusGB - no longer in EU/EEA
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA